SPRY - ARS Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$25.50
DETAILS
HIGH:
$26.00
LOW:
$25.00
MEDIAN:
$25.50
CONSENSUS:
$25.50
UPSIDE:
221.16%
About ARS Pharmaceuticals, Inc. (https://ars-pharma.com)
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Richard Lowenthal MSMSEL | Co-Founder, President, Chief Executive Officer & Director | 1966 | $3,480,290 USD |
| Sarina Tanimoto | Co-Founder & Chief Medical Officer | 1969 | $3,183,224 USD |
| Brian T. Dorsey | Chief Operating Officer | 1969 | $706,970 USD |
| Justin Chakma | Chief Business Officer | 1990 | $682,700 USD |
| Alexander A. Fitzpatrick | Chief Legal Officer & Secretary | 1967 | $677,145 USD |
| Eric Karas | Chief Commercial Officer | 1973 | $618,614 USD |
| Daniel Relovsky | Senior Vice President of Marketing | – | – |
| Kathleen D. Scott | Chief Financial Officer | – | – |
| Lynda Harris | Vice President of Human Resources | – | – |
| Robert Bell | Co-Founder & Chief Science Officer | – | – |